Free Trial

Nurix Therapeutics (NRIX) Earnings Date, Estimates & Call Transcripts

Nurix Therapeutics logo
$19.83 -0.21 (-1.05%)
(As of 12/20/2024 05:16 PM ET)

Nurix Therapeutics Latest Earnings Summary

Actual EPS
(Oct. 11)
-$0.67
Consensus EPS
(Oct. 11)
-$0.67

Nurix Therapeutics issued Q3 2024 earnings on October 11, 2024, reporting an EPS of -$0.67, which hit the consensus estimate of -$0.67. Quarterly revenue was reported to be $12.59 million, below the consensus estimate of $13.85 million. With a trailing EPS of -$2.91, Nurix Therapeutics' earnings are expected to grow next year, from ($2.81) to ($2.73) per share.

Get Nurix Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

NRIX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

NRIX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Nurix Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242-$0.87-$0.81-$0.84
Q2 20242-$0.88-$0.72-$0.80
Q3 20242-$0.90-$0.68-$0.79
Q4 20242-$0.92-$0.67-$0.80
FY 20248-$3.57-$2.88-$3.23
Q1 20251-$0.67-$0.67-$0.67
Q2 20251-$0.69-$0.69-$0.69
Q3 20251-$0.71-$0.71-$0.71
Q4 20251-$0.73-$0.73-$0.73
FY 20254($2.80)($2.80)($2.80)

Nurix Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
10/11/2024--$0.67-$0.67--$0.67$13.85M$12.59M
7/11/2024Q2 2024-$0.63-$0.71 -$0.08-$0.71$19.35M$12.09M
4/10/2024Q1 2024-$0.80-$0.76+$0.04-$0.76$14.58M$16.59M
2/15/2024Q4 2023-$0.51-$0.77 -$0.26-$0.77$30.66M$15.16M
10/12/2023Q3 2023-$0.84-$0.68+$0.16-$0.68$19.98M$18.47M
7/13/2023Q2 2023-$0.57-$0.45+$0.12-$0.45$21.96M$30.68M
Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)

You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.

Click Here to get the full details about Crypto’s Hidden Gem
4/13/2023Q1 2023-$0.90-$0.75+$0.15-$0.75$10.49M$12.69M
2/9/2023Q4 2022-$0.68-$0.87 -$0.19-$0.87$19.64M$6.78M

Nurix Therapeutics Earnings - Frequently Asked Questions

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earning data on Friday, October 11, 2024. Learn more on NRIX's earnings history.

In the previous quarter, Nurix Therapeutics (NASDAQ:NRIX) reported ($0.67) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.67). Learn more on analysts' earnings estimate vs. NRIX's actual earnings.

Nurix Therapeutics (NASDAQ:NRIX) has a recorded annual revenue of $56.42 million.

Nurix Therapeutics (NASDAQ:NRIX) has a recorded net income of -$143.95 million. NRIX has generated -$2.91 earnings per share over the last four quarters.

Nurix Therapeutics's earnings are expected to grow from ($2.81) per share to ($2.73) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:NRIX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners